Gwenn  Hansen net worth and biography

Gwenn Hansen Biography and Net Worth

Insider of Nurix Therapeutics
Gwenn M. Hansen, Ph.D. has served as Chief Scientific Officer of Nurix since June 2020 and served as the company’s Senior Vice President, Research from July 2019 through May 2020. Since joining Nurix in 2015, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery in addition to leading the discovery organization. Prior to joining Nurix, Gwenn was an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and served in a variety of discovery-focused roles at Lexicon Pharmaceuticals. Dr. Hansen holds a B.A. in Biology from Gustavus Adolphus College and a Ph.D. in Biomedical Sciences from the University of Tennessee-Knoxville.

What is Gwenn Hansen's net worth?

The estimated net worth of Gwenn Hansen is at least $715,098.61 as of January 30th, 2025. Dr. Hansen owns 55,937 shares of Nurix Therapeutics stock worth more than $715,099 as of March 25th. This net worth evaluation does not reflect any other assets that Dr. Hansen may own. Additionally, Dr. Hansen receives an annual salary of $702,750.00 as Insider at Nurix Therapeutics. Learn More about Gwenn Hansen's net worth.

How old is Gwenn Hansen?

Dr. Hansen is currently 53 years old. There are 4 older executives and no younger executives at Nurix Therapeutics. The oldest executive at Nurix Therapeutics is Dr. Arthur T. Sands M.D., Ph.D., CEO, President & Director, who is 62 years old. Learn More on Gwenn Hansen's age.

What is Gwenn Hansen's salary?

As the Insider of Nurix Therapeutics, Inc., Dr. Hansen earns $702,750.00 per year. The highest earning executive at Nurix Therapeutics is Dr. Arthur T. Sands M.D., Ph.D., CEO, President & Director, who commands a salary of $986,320.00 per year. Learn More on Gwenn Hansen's salary.

How do I contact Gwenn Hansen?

The corporate mailing address for Dr. Hansen and other Nurix Therapeutics executives is , , . Nurix Therapeutics can also be reached via phone at 415-660-5320 and via email at wolffe@wheelhouselsa.com. Learn More on Gwenn Hansen's contact information.

Has Gwenn Hansen been buying or selling shares of Nurix Therapeutics?

Over the course of the past ninety days, Gwenn Hansen has sold $73,246.50 in Nurix Therapeutics stock. Most recently, Gwenn Hansen sold 3,690 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a transaction totalling $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. Learn More on Gwenn Hansen's trading history.

Who are Nurix Therapeutics' active insiders?

Nurix Therapeutics' insider roster includes Pierre Beaurang (Insider), Gwenn Hansen (Insider), and Christine Ring (General Counsel). Learn More on Nurix Therapeutics' active insiders.

Are insiders buying or selling shares of Nurix Therapeutics?

In the last twelve months, insiders at the sold shares 22 times. They sold a total of 101,331 shares worth more than $2,219,676.58. The most recent insider tranaction occured on March, 3rd when CFO Houte Hans Van sold 5,825 shares worth more than $84,404.25. Insiders at Nurix Therapeutics own 7.2% of the company. Learn More about insider trades at Nurix Therapeutics.

Information on this page was last updated on 3/3/2025.

Gwenn Hansen Insider Trading History at Nurix Therapeutics

Gwenn Hansen Buying and Selling Activity at Nurix Therapeutics

This chart shows Gwenn Hansen's buying and selling at Nurix Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$73ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Nurix Therapeutics Company Overview

Nurix Therapeutics logo
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $12.58
Low: $12.54
High: $13.54

50 Day Range

MA: $16.76
Low: $12.58
High: $20.15

2 Week Range

Now: $12.58
Low: $11.90
High: $29.56

Volume

847,242 shs

Average Volume

872,085 shs

Market Capitalization

$954.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18